Welcome to Chiesi
United states of America
Home page > News
Moderna and Chiesi Group Establish Collaboration to Discover and Develop mRNA Therapeutics for Pulmonary Arterial Hypertension (PAH).
17-09-2020
Protalix BioTherapeutics Announces Completion of the Treatment Period for its Phase III BRIGHT Clinical Trial of Pegunigalsidase Alfa (PRX-102) for the ProposedTreatment of Fabry Disease
25-08-2020
Chiesi USA, Inc. Earns 2020 Life Sciences Award by Triangle Business Journal
24-08-2020
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce U.S. Food and Drug Administration Acceptance of Biologics License Application (BLA) for Pegunigalsidase Alfa for the Proposed Treatment of Fabry Disease and Grants Priority Review
11-08-2020
Chiesi publishes its annual report: Group generates almost €2 billion and obtains B Corp certification in 2019
16-07-2020
Bioasis and Chiesi Group to Host Webcast on July 16, 2020
10-07-2020
Thomas Eichholtz appointed new Head of Global Research and Development at the Chiesi Group
10-07-2020
Bioasis and Chiesi Group Announce Rare Diseases Strategic Alliance
30-06-2020
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Submission of Biologics License Application to U.S. Food and Drug Administration for Pegunigalsidase Alfa for the Treatment of Fabry Disease
28-05-2020
Chiesi Group Receives FDA Approval for Ferriprox® (deferiprone) twice-a-day tablets
21-05-2020
Chiesi Global Rare Diseases Recognizes Fabry Disease Awareness Month and Launches “Fabry Focus on Health” Educational Series to Support Patients and Caregivers During COVID-19 Pandemic
24-04-2020
Chiesi USA increases support measures for employees, patients and community partners in response to COVID-19 pandemic
31-03-2020
Chiesi USA certified as a Great Place to Work® in 2019
02-03-2020
Chiesi Global Rare Diseases Recognizes Rare Disease Day and Highlights Plans to Expand Focus on Patient Advocacy in 2020
27-02-2020
Chiesi in the Community donates nearly $1 million in 2019
26-02-2020
Chiesi Group Announces Establishment of New Global Rare Diseases Division
06-02-2020
Chiesi USA, Inc. Receives Top Employer in the U.S. Certification for 2020
30-01-2020
Chiesi Group and Apotex Inc. finalize agreement for acquisition of Ferriprox® (deferiprone)
13-01-2020
Chiesi and Durham Bulls Partnership Culminates in $15,000 to Triangle Nonprofits
04-09-2019
Chiesi Group confirms positive trend to date for 2019
09-07-2019
Chiesi Group is the largest pharmaceutical group in the world to be awarded B Corp certification
06-06-2019
Triangle Business Journal Recognizes Chiesi USA, Inc. With Third Consecutive Corporate Philanthropy Award
05-06-2019
Paolo Chiesi is Appointed Honorary Doctor at Karolinska Institutet
15-05-2019
Chiesi Named Signature Sponsor of the Triangle March for Babies Walk & 5K Run
26-04-2019
Chiesi and Durham Bulls Partnership Steps up to Bat for Local Charities
22-04-2019
Chiesi USA Promotes Medical Affairs Head to Support Continued Corporate Growth
16-04-2019
Chiesi USA, Inc. Moves to New Headquarters in Regency Woods II
26-02-2019
Chiesi Joins National Organization for Rare Disorders (NORD)® Corporate Council
21-02-2019
Chiesi USA, Inc. Receives Top Employer in the US Certification for 2019
31-01-2019
Chiesi in the Community Donates approximately $850,000 in 2018
28-01-2019
Chiesi USA Attains Public Benefit Corporation Status, Pledges to Advance Positive Community Impact
11-01-2019
Chiesi Salutes Neonatal Intensive Care Unit Staff in Honor of Prematurity Awareness Month®
14-11-2018
Chiesi Salutes Nurses Surrounding Neonatal Nurses Day 2018
18-09-2018
Chiesi Partnership with Durham Bulls Closes Season with $15,000 to Area Nonprofits
06-09-2018
Chiesi USA, Inc. Named a Best Place to Work
22-08-2018
Chiesi Foundation Onlus Issues 2018 Call for Scientific Research Proposals
14-08-2018
Chiesi and Holostem Announce FDA Orphan Drug Designation for GPLSCD01 for treatment of Limbal Stem Cell Deficiency (LSCD)
12-06-2018
